Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris

G R JONES, M A MIR

From the Department of Medicine, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff

SUMMARY We compared the antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in a randomised manner in 12 patients with stable angina pectoris. An exercise test was performed initially and in the 24th hour after a single daily dose of 160 mg of each beta-blocker at the end of a two week treatment period. In addition, glyceryl trinitrate consumption, anginal attack rate, and activity scores were recorded. No titration studies to an equivalent degree of beta-blockade were undertaken; a fixed dose was used even though these drugs are not equipotent.

Conventional propranolol in a single daily dose of 160 mg was as effective in controlling the frequency of anginal attacks as long acting propranolol and sustained release oxprenolol. Exercise tolerance was less with sustained release oxprenolol than with conventional propranolol, long acting propranolol, and nadolol. Nadolol produced a significantly greater reduction in exercise-induced tachycardia than did long acting propranolol, sustained release oxprenolol, and conventional propranolol, and also the lowest anginal attack rate, the lowest trinitrin consumption, and significantly less ST segment depression than the other three.

These findings suggest that nadolol is more potent than long acting propranolol, sustained release oxprenolol, and conventional propranolol, and the antianginal benefit at the 24th hour relates to the degree of beta-adrenoreceptor blockade achieved.

Conventional beta-adrenoreceptor blocking drugs are given divided into three or four daily doses because of their short serum half-life. Recently, various long acting preparations have been introduced with the expectation that a single daily dose would provide a sustained antianginal effect, ensure 24 hour beta-adrenoreceptor blockade, and achieve improved patient compliance. So far no clinical study has shown any improvement in the antianginal effect of a divided dose regimen, as compared with the same dose taken on a single once-daily basis. It also remains to be established that the antianginal effect of a long acting beta-adrenoreceptor blocking drug extends its antianginal efficiency to the 24th hour before the next dose is due.

This study was undertaken to compare four beta-adrenoreceptor drugs for their antianginal efficiency in the 24th hour after a single daily dose treatment period. Propranolol was used to represent a conventional beta-adrenoreceptor blocker: the three other preparations were chosen because in each case the mechanism for a prolonged serum half-life was different.

Patients and methods

PATIENTS Twelve patients with an average age of 56 years (range 39 to 71) with stable angina pectoris were studied. In all of these carefully selected patients, angina could be reproduced during bicycle (ergometer) exercise and in all cases ST depression of more than 1 mm for 0.08 s duration on V5 developed. None of the patients had any evidence of heart failure. Eleven patients had been taking a beta-adrenoreceptor blocking drug for more than six months and the twelfth patient was started on long acting propranolol six weeks before his entry into this study. The dose of the drug in each was 160 mg either in divided doses or as a long acting
preparation (Table 1), since most patients with angina tend to respond to this dose.1–5 None of the patients was taking digitalis or a diuretic. Two patients smoked cigarettes. Smoking habits remained unchanged throughout the study. No cigarettes were allowed the morning before the tests were performed.

The purpose and the nature of the investigation was explained to each patient and all consented to participate in the study.

**DESIGN OF INVESTIGATION**

The exercise procedure was essentially in accordance with the one designed by Redwood et al.5 All patients were brought to the exercise laboratory (temperature 20° to 24°C) on at least three weekly occasions before the definitive studies. They exercised upright on a bicycle ergometer (Monark, Sweden) and pedalled steadily in time with a metronome at 50 rpm. The exercise capacity was assessed by increasing the work load by 300 kilopondmetres (kpm) every four minutes until the onset of angina. The heart rate was monitored continuously through a V5 lead. Each patient was entered into the study after the anginal point had become reproducible. On the day of the definitive test, the patients were studied in the morning after 30 minutes rest, and asked not to take any glyceryl trinitrate (GTN) on that day. Each patient was exercised exactly 23 hours after the last dose of a beta-adrenoreceptor blocker. At the point of onset of angina the total exercise load, duration of exercise, and heart rate were recorded. A 12 lead electrocardiogram was taken before and within two minutes of the exercise. ST segment depression in all leads (≥ST) was documented. This exercise procedure was carried out at the entry of a patient into the study, at each cross over point, and at the end of the study.

Four beta-adrenoreceptor blocking agents, conventional propranolol, long acting propranolol, sustained release oxprenolol, and nadolol were studied. Propranolol was chosen as a conventional beta-adrenoreceptor blocking drug with a short serum half-life. The three long acting preparations achieve a long serum half-life by different mechanisms: long acting propranolol allows slow diffusing of the active drug from microspheres, in slow release oxprenolol, oxprenolol is leached out of a polymer colander, and

---

Table 1  **Comparison of patient well-being, job, social, and home activity* scores between pretrial therapy and four beta-adrenoreceptor drugs**

<table>
<thead>
<tr>
<th>Patient No. and pretrial treatment</th>
<th>Slow release oxprenolol</th>
<th>Long acting propranolol</th>
<th>Nadolol</th>
<th>Conventional propranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Well being</td>
<td>Activity</td>
<td>Well being</td>
<td>Activity</td>
</tr>
<tr>
<td>1 SRO 160 mg od</td>
<td>6</td>
<td>12</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>2 SRO 160 mg od</td>
<td>5</td>
<td>10</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>3 Oxprenolol 80 mg bd</td>
<td>8</td>
<td>11</td>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>4 LAP 160 mg od</td>
<td>4</td>
<td>17</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>5 Oxprenolol 80 mg bd</td>
<td>7</td>
<td>12</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>6 SRO 160 mg od</td>
<td>6</td>
<td>12</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>7 LAP 160 mg od</td>
<td>7</td>
<td>13</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>8 LAP 160 mg od</td>
<td>8</td>
<td>18</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>9 CP 40 mg qds</td>
<td>6</td>
<td>13</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>10 SRO 160 mg od</td>
<td>7</td>
<td>16</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>11 Oxprenolol 40 mg qds</td>
<td>7</td>
<td>12</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>12 LAP 160 mg od</td>
<td>10</td>
<td>18</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Mean</td>
<td>7</td>
<td>13</td>
<td>6</td>
<td>11</td>
</tr>
</tbody>
</table>

*For explanation see methods.
SRO, slow release oxprenolol; LAP, long acting propranolol; CP, conventional propranolol.
Long acting beta-adrenoceptor blockers in angina

nadolol has an intrinsically long plasma half-life, being slowly excreted. Each drug was administered in a single morning dose of 160 mg as this is a likely dosage to be used in clinical practice, though, dose for dose, nadolol is a slightly more potent drug than propranolol. Unfortunately, identical capsules could not be obtained but “double-blinding” was maintained by providing each patient with a two week supply in an unlabelled bottle so that neither the investigator nor the patient knew the exact identity of the drug inside the bottle. The patients were randomised and each received a bottle for each period identified by its period number. The bottles were collected at the end of each cross over period and stored until the end of the study; these were then checked for unused drugs. The code key was sealed until the end of the study.

PATIENT ASSESSMENT
At the start of each treatment period the patients were given record cards to note the number of anginal attacks and glyceryl trinitrate consumption. They also noted whether they had to reduce, or if they could increase, the level of a named activity at home (for example sewing, running, digging, etc.), socially (for example dancing, playing games, etc.), and at work (for example climbing stairs, etc.). A weekly points-scoring system was designed by which no-change in any activity was awarded 2. Thus, in each two week period a patient scored 12 if he noticed no change in any of the three activities, six if he could undertake an additional activity in each, and 18 if he noticed a deterioration in social, home, and job activities. These data were analysed by Friedman’s test.

LABORATORY MEASUREMENTS
Routine laboratory investigations were carried out in all patients. Blood was collected for plasma beta-blocker levels 23 hours after the last dose in each patient at the time of the exercise test, and the plasma was stored at −20°C. Plasma concentrations of drugs were measured by the respective pharmaceutical laboratories.

STATISTICAL METHODS
Conventional statistical methods were used. Anginal attacks, glyceryl trinitrate consumption, and scores for activity and well-being were analysed by a nonparametric method using Friedman’s rank test. Changes in heart rate, ΣST depression, and work load were studied by analysis of variance fitting for patient, period, treatments, and carryover. Significance was assessed by using an ‘F’ test after which, if significant, t tests were used to compare pairs of treatments, using the residual mean square in the estimate of the standard error.

Results

ANTIANGINAL EFFICIENCY
The glyceryl trinitrate consumption and anginal attack rate were lowest during the nadolol period of two weeks (Table 2). Patients were able to increase their activity either at home, at work, or socially during the nadolol and long acting propranolol periods. The score for these activities was better during nadolol and long acting propranolol, as compared with pretiral and conventional propranolol periods (Table 1). The sense of well-being was not easy to define, but the patients complained that though the anginal frequency was not significantly different between various periods, the attacks tended to occur in clusters in the evening and early morning during conventional propranolol and slow release oxprenolol as opposed to long acting propranolol and nadolol periods.

EXERCISE PERFORMANCE
The maximal exercise performance to the point of angina was not significantly different between propranolol, long acting propranolol, and nadolol (Fig. 1), but the mean kpm achieved was lowest during slow release oxprenolol and highest during nadolol. Interestingly, 23 hours after a single dose of conventional propranolol, the exercise performance was as good as long acting propranolol and better than slow release oxprenolol.

The mean resting heart rate 23 hours after the last dose of nadolol was significantly lower (p<0.05) at 57±4 bpm (SEM) than with slow release oxprenolol and conventional propranolol (Fig. 2). The mean resting pulse rate was 63±4 bpm during long acting propranolol, 70±4 bpm during slow release oxprenolol, and 71±6 bpm during conventional propranolol. There was no significant difference between these three. The exercise-induced tachycardia at the anginal point was lowest after nadolol (93 bpm) and the difference between nadolol and the two other long acting beta-blockers was highly significant (p<0.01). The two long acting formulations, slow release oxprenolol and long acting propranolol, also

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Antianginal efficiency of four beta-adrenoceptor blocking preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Propranolol</td>
</tr>
<tr>
<td>Glyceryl trinitrate consumption (2 wk) mean</td>
<td>17</td>
</tr>
<tr>
<td>Anginal attacks (2 wk) mean</td>
<td>15</td>
</tr>
</tbody>
</table>
showed a significant reduction in exercise induced tachycardia as compared with conventional propranolol. The mean heart rate at the onset of angina was 115±4 bpm after slow release oxprenolol, 107±3 bpm after long acting propranolol, and 130±4 bpm after conventional propranolol.

ΣST SEGMENT DEPRESSION
The mean of the total ST segment depression in all leads (ΣST) after exercise was 2.13±0.41 (SEM) mm 23 hours after nadolol, 4.9±0.98 mm after slow release oxprenolol, 4.04±0.64 mm after long acting propranolol, and 3.96±0.73 mm after conventional propranolol (Fig. 3). Σ ST depression was significantly lower (p<0.05) after nadolol as compared with the other three preparations.

SIDE EFFECTS
Bradycardia after nadolol did not produce any symptoms. One patient on nadolol and one on conventional propranolol complained of cold hands and feet and numbness. There was no objective evidence of peripheral neuropathy, and electromyographic studies showed no conduction impairment.

PLASMA CONCENTRATION
The mean plasma drug concentration was highest in the 24th hour after nadolol (134.6±14.4 SEM) and lowest at 13±4 ng/ml after conventional propranolol. The high serum level of nadolol was in keeping with a significant reduction in the simultaneously studied exercise-induced tachycardia (Fig. 2), but it is of interest to note that the low level of conventional propranolol was also accompanied by a lower exercise
heart rate than would be expected without beta-blockade. Long acting propranolol and slow-release oxprenolol occupied intermediate places with the 24th hour mean plasma levels of 26 and 46 ng/ml, respectively. The drug was undetectable in the plasma of four patients in the slow release oxprenolol group, one in the conventional propranolol group, and one in the long acting propranolol group.

Discussion

This study showed that there was no significant difference in the frequency of anginal attacks and glyceryl trinitrate consumption between the treatment periods. The overall patient preference was in favour of long acting propranolol and nadolol (Table 1); the patients felt better subjectively, the anginal attacks did not occur in clusters towards the evenings and early mornings (as happened with conventional propranolol and slow release oxprenolol), they were able to lead a more active life, and, with nadolol, the anginal attack rate as well as the glyceryl trinitrate consumption were less than with the other three drugs (Table 2). An interesting finding was that a single dose of conventional propranolol was as effective in controlling the frequency of angina as long acting formulations of propranolol and oxprenolol. The mean propranolol level in the 24th hour was 13±4 ng/ml, which is capable of producing a significant beta-blockade.\textsuperscript{4,5} Though plasma levels of slow release oxprenolol were higher than conventional propranolol, a lower work load was achieved during the former. Other workers' data\textsuperscript{11} suggest that dose for dose propranolol is slightly more effective in angina than oxprenolol and that nadolol is more potent than propranolol.\textsuperscript{8}

The absorption of slow release oxprenolol may be erratic from the gut since four of the 12 patients had no oxprenolol in their plasma in the 24th hour. As slow release oxprenolol was the mainstay of their treatment during a period in which they experienced an increased frequency of anginal attack, and since the final tablet count failed to suggest a lack of compliance, it seems likely that either the drug was not absorbed, or, for some reason, was rapidly excreted in these four patients.

Nadolol is a newly introduced beta-blocker with a long serum half-life of 16 to 24 hours.\textsuperscript{7} This study showed that it maintained high plasma levels in the 24th hour after a single daily dose treatment and produced a highly significant degree of beta-blockade as shown by suppression of exercise induced tachycardia compared with slow release oxprenolol and long acting propranolol. The post-exercise \( \Delta \) ST segment depression was significantly lower than with the other three preparations.

Our studies indicate that when given as a single dose the antianginal efficacy in the 24th hour relates to the degree of beta-adrenoreceptor blockade achieved at that time, and 160 mg nadolol was the most effective and 160 mg slow release oxprenolol the least effective in achieving this.

We are indebted to Dr J McAinsh (ICI Pharmaceuticals Ltd, Macclesfield) and to Drs M E Tenneson and S B Biggs (Squibb Research and Development, Liverpool) for measurement of plasma drug concentrations, to ICI Pharmaceuticals and to E R Squibb and Sons, Hounslow, for the supply of drugs. We should like to thank Drs T M Hayes and J H Lazarus, consultant physicians, for allowing us to study some of the patients under their care.

References


Requests for reprints to Dr M A Mir, University Hospital of Wales, Heath Park, Cardiff CF4 4XW.
Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoceptor blocking agents in stable angina pectoris.

G R Jones and M A Mir

Br Heart J 1981 46: 503-507
doi: 10.1136/hrt.46.5.503

Updated information and services can be found at:
http://heart.bmj.com/content/46/5/503

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/